Executive summary of IPITA-TTS opinion leaders report on the future of b-cell replacement

Transplantation

Volumn 100, Issue 7, 2016, Pages e25-e31

  Markmann, James F ^a   Bartlett, Stephen T ^b   Johnson, Paul ^c   Korsgren, Olle ^d   Hering, Bernhard J ^e   Scharp, David ^f,g   Kay, Thomas W H ^h,i   Bromberg, Jonathan ^b   Odorico, Jon S ^j   Weir, Gordon C ^k   Bridges, Nancy ^l   Kandaswamy, Raja ^e   Stock, Peter ^m   Friend, Peter ^c   Gotoh, Mitsukazu ⁿ   Cooper, David K C ^o   Park, Chung Gyu ^p   O'Connell, Philip J ^q   Stabler, Cherie ^r   Matsumoto, Shinichi ^s,t   Ludwig, Barbara ^u,v   Choudhary, Pratik ^w   Khovatchev, Boris ^x   Rickels, Michael R ^y   Sykes, Megan ^z   Wood, Kathryn ^c   Kraemer, Kristy ^l   Hwa, Albert ^aa   Stanley, Edward ^ab,ac   Ricordi, Camillo ^ad   Zimmerman, Mark ^ae   Greenstein, Julia ^aa   Montanya, Eduard ^af   Otonkoski, Timo ^ag   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f Prodo Laboratories Inc   (United States)

^g Scharp Lacy Research Institute   (United States)

^h ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^m UNIVERSITY OF SAN FRANCISCO   (United States)

ⁿ FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^o UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^p Seoul National University   (South Korea)

^q UNIVERSITY OF SYDNEY   (Australia)

^r University of Florida   (United States)

^s OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^t NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^u DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^v DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^w KING'S COLLEGE LONDON   (United Kingdom)

^x UNIVERSITY OF VIRGINIA   (United States)

^y UNIVERSITY OF PENNSYLVANIA   (United States)

^z NewYork Presbyterian Hospital   (United States)

^aa Juvenile Diabetes Research Foundation International   (United States)

^ab MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^ac MONASH UNIVERSITY   (Australia)

^ad UNIVERSITY OF MIAMI   (United States)

^ae JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^af HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^ag UNIVERSITY OF HELSINKI   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ALLOIMMUNITY; ALLOTRANSPLANTATION; ARTICLE; ARTIFICIAL PANCREAS; AUTOIMMUNITY; CELL ENCAPSULATION; CELL PROLIFERATION; CELL REGENERATION; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL DOCUMENTATION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RESEARCH PRIORITY; STANDARDIZATION; STEM CELL; XENOTRANSPLANTATION; ANIMAL; CYTOLOGY; DIABETES MELLITUS, TYPE 1; MEDICAL SOCIETY; METABOLISM; ORGANIZATION; PANCREAS; PANCREAS ISLET; PIG; PROCEDURES; REGENERATION; UNITED STATES; XENOGRAFT;

ANIMALS; CELL PROLIFERATION; CONGRESSES AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; PANCREAS; PANCREAS TRANSPLANTATION; REGENERATION; SOCIETIES, MEDICAL; SWINE; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 84976324410     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001054     Document Type: Article

References (33)

1. Bartlett ST, Markmann JF, Johnson P, et al. Report from IPITA-TTS Opinion Leaders Meeting on the future of-cell replacement. Transplantation. 2016;100(Suppl 2S):S1-S44.
2. Venstrom JM, McBride MA, Rother KI, et al. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA. 2015;313:2017-2023.
3. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl JMed. 2000;343:230-238.
4. Hering BJ, Clarke WR, Bridges ND, et al. Phase 3 trial of human islets in type 1 diabetes. 2015; submitted.
5. CIT 07 islet transplantation. http://citregistry. org/.
6. Hering BJ, Wijkstrom M, Graham ML, et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med. 2006;12:301-303.
7. Cardona K, Korbutt GS, Milas Z, et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med. 2006;12:304-306.
8. van der Windt DJ, Bottino R, Casu A, et al. Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant. 2009;9:2716-2726.
9. Hecht G, Eventov-Friedman S, Rosen C, et al. Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model. Proc Natl Acad Sci U S A. 2009;106:8659-8664.
10. Thompson P, Cardona K, Russell M, et al. CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant. 2011;11:947-957.
11. Thompson P, Badell IR, Lowe M, et al. Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function. Am J Transplant. 2011;11:2593-2602.
12. Thompson P, Badell IR, Lowe M, et al. Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival. Am J Transplant. 2012;12:1765-1775.
13. Jung KC, Park CG, Jeon YK, et al. In situ induction of dendritic cell-based T cell tolerance in humanized mice and nonhuman primates. J ExpMed. 2011;208:2477-2488.
14. Kang HJ, LeeH, Ha JM, et al. The role of the alternative complement pathway in early graft loss after intraportal porcine islet xenotransplantation. Transplantation. 2014;97:999-1008.
15. Bottino R, Wijkstrom M, van der Windt DJ, et al. Pig-to-monkey islet xenotransplantation using multi-transgenic pigs. Am J Transplant. 2014; 14:2275-2287.
16. Dufrane D, Goebbels RM, Gianello P. Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation. 2010;90: 1054-1062.
17. Veriter S, Gianello P, Igarashi Y, et al. Improvement of subcutaneous bioartificial pancreas vascularization and function by coencapsulation of pig islets and mesenchymal stem cells in primates. Cell Transplant. 2014;23:1349-1364.
18. Matsumoto S, Tan P, Baker J, et al. Clinical porcine islet xenotransplantation under comprehensive regulation. Transplant Proc. 2014;46: 1992-1995.
19. Sun Y, Ma X, Zhou D, et al. Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J Clin Invest. 1996; 98:1417-1422.
20. Bennet W, Sundberg B, Lundgren T, et al. Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation. 2000;69:711-719.
21. Kirchhof N, Shibata S, Wijkstrom M, et al. Reversal of diabetes in non-immunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection. Xenotransplantation. 2004; 11:396-407.
22. Goto M, Johansson H, Maeda A, et al. Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets. Transplantation. 2004;77:741-747.
23. Van der Windt DJ, Bottino R, Casu A, et al. Rapid loss of intraportally transplanted islets: An overview of pathophysiology and preventive strategies. Xenotransplantation. 2007;14:288-297.
24. Goto M, Tjernberg J, Dufrane D, et al. Dissecting the instant bloodmediated inflammatory reaction in islet xenotransplantation. Xenotransplantation. 2008;15:225-234.
25. Hawthorne WJ, Salvaris EJ, Phillips P, et al. Control of IBMIR in neonatal porcine islet xenotransplantation in baboons. Am J Transplant. 2014;14: 1300-1309.
26. De Voss P, editor. Cell Encapsulation and Drug Delivery. In Advanced Drug Reviews.). Elsevier Press; 2014:67 & 68:1-154.
27. Scharp DW, Marchetti P. Encapsulated islets for diabetes therapy: history, current progress, and critical issues requiring solution. Adv Drug Deliv Rev. 2014;67-68:35-73 In "Cell Encapsulation and Drug Delivery", De Voss P (Ed) 2014; 67-68:1-154.
28. Renard E, Cobelli C, Zisser HC, et al. Artificial pancreas outpatient: A new diabetes ecosystem. J Diabetes Sci Technol. 2013;7:1411-1415.
29. Peyser T, Dassau E, Breton M, et al. The artificial pancreas: current status and future prospects in the management of diabetes. Ann N Y Acad Sci. 2014;1311:102-103.
30. Thabit H, Tauschmann M, Allen JM, et al.; APCam Consortium; AP@home Consortium. Home Use of an Artificial Beta Cell in Type 1 Diabetes. N Engl J Med. 2015;373:2129-2140.
31. Nikolic B, Takeuchi Y, Leykin I, et al. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes. 2004;53:376-383.
32. Nikolic B, Onoe T, Takeuchi Y, et al. Distinct requirements for achievement of allotolerance versus reversal of autoimmunity via nonmyeloablative mixed chimerism induction in NOD mice. Transplantation. 2010;89:23-32.
33. Li HW, Sykes M. Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol. 2012;1:403-416.